200 Bellevue, WA 98006, USA * Correspondence: Loren Pickart Academic Editors: Luis Martinez and Michael Fossel Received: June 8, 2018 | Accepted: August 2, 2018 | Published: August 16, 2018 OBM Geriatrics 2018 , Volume 2, Issue 3 doi:10.21926/obm.geriatr.1803009 Recommended citation: Pickart L, Margolina A
R.et al (2023)
patients had CKD stages 1 to 5 diagnosed by Kidney Disease: Improving Global Outcomes guidelines plus at least 3 months of one of the following: moderate to severe albuminuria regardless of estimated glomerular filtration rate (eGFR), eGFR less than 90 mL/min/1.73 m 2 with structural abnormalities of the kidney or urinary sediment abnormalities, or eGFR less than 60 mL/min/1.73 m 2 Efficacy End Points: Reduction in all-cause death, major adverse cardiovascular events (composite outcomes), and cardiovascular death
Maximum benefits usually occur over several months of consistent treatment
Several employees have sued health insurance companies for excluding coverage of GLP-1 medications prescribed solely to treat obesity, arguing that such obesity exclusion constitutes disability discrimination under the ACA